2018 年 11 月 29 日，那不勒斯“免疫疗法研讨会 2018”的激烈辩论。

The great debate at "Immunotherapy Bridge 2018", Naples, November 29th, 2018.

机构信息

Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS Fondazione "G. Pascale", Naples, Italy.

Parker Institute for Cancer Immunotherapy Research Center, UCSF, San Francisco, California, USA.

出版信息

J Immunother Cancer. 2019 Aug 15;7(1):221. doi: 10.1186/s40425-019-0683-0.

DOI:10.1186/s40425-019-0683-0

PMID:31416487

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6696687/

Abstract

As part of the 2018 Immunotherapy Bridge congress (November 28-29, Naples, Italy), the Great Debate session featured counterpoint views from leading experts on four topical clinical issues in immunotherapy today. These were: the relative importance of adaptive versus innate immunity in the anti-cancer immune response; the merits of combination versus sequential immunotherapy regimens in the treatment of cancer; the advantages and disadvantages of murine models of cancer versus humans in order to evaluate immunotherapy; and whether or not mechanisms of resistance to immunotherapy differ between different cancers. Discussion of these important topics are summarised in this report.

摘要

作为 2018 年免疫治疗桥大会（11 月 28 日至 29 日，意大利那不勒斯）的一部分，这场大辩论会的特色是，就当今免疫治疗的四个热门临床问题，邀请了来自领先专家的针锋相对的观点。这些问题是：适应性免疫与固有免疫在抗癌免疫反应中的相对重要性；联合免疫治疗方案与序贯免疫治疗方案在癌症治疗中的优缺点；为了评估免疫治疗，癌症的鼠模型与人相比有哪些优势和劣势；以及不同癌症的免疫治疗耐药机制是否存在差异。本报告总结了对这些重要主题的讨论。